Abstract

Donaldson Company, Inc. will release fiscal fourth-quarter 2026 results on August 26, 2026, Pre-Mkt; this preview outlines consensus forecasts, a concise review of the prior quarter’s performance, segment dynamics, and what to monitor for potential upside or downside this reporting cycle.

Market Forecast

Consensus points to fiscal fourth-quarter revenue of 1.04 billion US dollars, up 9.64% year over year, with adjusted EPS estimated at 1.13, up 10.82% year over year; the operating bridge implies EBIT of 182.90 million US dollars, up 13.74% year over year. Margin-specific forecasts are not broadly disclosed; investors are watching whether last quarter’s gross profit margin baseline can hold or improve and whether net profit margin shows sequential or annual expansion alongside the forecast revenue growth.

Within the core revenue base, Mobile Solutions and Industrial Products remain the primary drivers of quarterly throughput and mix; commentary will likely center on price realization, aftermarket volume resilience, and any signs of order normalization. The most promising growth vector remains Life Sciences given its higher-margin profile and expanding application set; last quarter revenue was 83.50 million US dollars, and while year-over-year growth figures are not disclosed, management emphasis and external previews consistently flag this business as a key margin accretor.

Last Quarter Review

For fiscal third quarter 2026 (ended April 30, 2026), Donaldson Company, Inc. delivered revenue of 995.10 million US dollars, gross profit margin of 34.42%, GAAP net profit attributable to shareholders of 118.00 million US dollars, net profit margin of 11.87%, and adjusted EPS of 1.06, up 7.07% year over year.

A notable highlight was the full-year guidance calibration: management narrowed fiscal 2026 adjusted EPS to 3.94–4.01, framing the pathway for operating discipline into the fiscal fourth quarter. On the business mix, Mobile Solutions contributed 629.90 million US dollars and Industrial Products 281.70 million US dollars, while Life Sciences posted 83.50 million US dollars; the distribution underscores how aftermarket and equipment exposures underpin the top line, with Life Sciences positioned as a positive mix effect.

Current Quarter Outlook

Main Business: Mobile Solutions and Industrial Products

The core engine of this quarter’s print remains the Mobile Solutions and Industrial Products portfolio, which collectively represented the majority of the prior quarter’s revenue. With consensus revenue at 1.04 billion US dollars, up 9.64% year over year, the implied demand environment points to stable unit activity augmented by pricing carryover and mix. Aftermarket streams (replacement filters and related consumables) tend to provide steadier cadence in periods when new equipment orders fluctuate, helping smooth factory utilization and supporting gross margin consistency versus the 34.42% baseline reported in the fiscal third quarter.

Price discipline and product mix will be the levers to watch. If pricing realized in prior quarters is sustained while input costs and logistics remain contained, gross profit dollars should rise in line or ahead of revenue, improving operating leverage. Conversely, any evidence of order deferrals in OEM channels or an unfavorable mix shift to lower-value SKUs could mute conversion of the 9.64% revenue growth into operating income, even as aftermarket replenishment provides a partial buffer.

Operating expense management is the secondary determinant for earnings power. The prior-quarter EBIT of 165.10 million US dollars (up 7.84% year over year) set a credible execution bar; consensus now embeds 182.90 million US dollars for the current quarter, implying healthier leverage. Delivering on that level requires that any incremental spend tied to commercial initiatives and R&D remains synchronized with the revenue curve. Investors will parse commentary on order intake quality, backlog composition, and shipment timing to gauge whether the fourth quarter’s momentum sustains into the early months of the next fiscal year.

Most Promising Business: Life Sciences

Life Sciences remains the company’s most promising margin-accretive vector, with last quarter’s 83.50 million US dollars providing a growing foundation for scale. The segment typically benefits from higher-value applications and qualification-driven customer stickiness, which can translate into better pricing power and sustained gross margin uplift relative to the company average. Even if the near-term revenue base is smaller than core filtration lines, incremental contributions from Life Sciences can produce outsized effects on blended margins, especially if product mix tilts toward solutions with robust validation and consumables pull-through.

The watchpoint is execution consistency—order timing, validation milestones, and delivery cadence can create quarter-to-quarter variability even when the underlying trajectory is constructive. As the segment scales, supply chain orchestration and inventory positioning will influence margin delivery. The company’s commentary around new product adoption and customer pipeline conversion will help the market assess how quickly Life Sciences can step up from its 83.50 million US dollars quarterly base toward a more material earnings driver. A stable or expanding contribution here would support the consensus call for adjusted EPS growth of 10.82% year over year this quarter.

A further angle is mix migration within higher-margin categories. If Life Sciences accelerates relative to Mobile Solutions and Industrial Products, blended gross margin could outpace volume growth, enabling EBIT to track ahead of revenue. Conversely, if revenue growth in the quarter skews more toward lower-margin product families due to delivery timing, the EBIT cadence may hew closer to consensus even as revenue clears the 1.04 billion US dollars threshold.

What Will Most Impact the Stock This Quarter

The first swing factor is revenue versus the 1.04 billion US dollars consensus. An in-line top line will likely keep the focus on margin quality, while a modest beat accompanied by constructive backlog and order commentary would fortify the case for balanced growth exiting the fiscal year. Because last quarter’s revenue rose 5.85% year over year and the current quarter implies 9.64%, the market is effectively pricing an acceleration; confirmation of that acceleration—particularly without disproportionate discounting or promotional activity—would be taken as a sign of healthy demand and pricing resilience.

The second determinant is margin trajectory relative to the 34.42% gross margin baseline and the 11.87% net margin achieved last quarter. Investors will assess whether product mix, pricing, and operating efficiency are sufficient to defend or lift margins in the face of any cost noise. Commentary on input costs, logistics, and productivity initiatives will be critical. If gross profit conversion appears robust, the implied 182.90 million US dollars EBIT and 1.13 adjusted EPS should be reachable, supporting the narrowed full-year EPS range of 3.94–4.01.

Capital deployment is the third factor. The company’s consistent quarterly dividend of 0.32 US dollars per share reinforces a disciplined cash return framework. Any indications of incremental flexibility—such as sustained cash generation above historical patterns—would be considered supportive for the equity narrative. The balance between organic investments, potential bolt-on activity tied to higher-margin categories, and shareholder returns will color how the market values the durability of mid-teens EBIT growth implied for the quarter.

Analyst Opinions

Bullish-to-bearish commentary across the previews we reviewed skews decisively positive, with a clear majority emphasizing constructive near-term dynamics and limited outright negative calls. The prevailing view aligns around three points: the company exceeded expectations last quarter on both revenue and adjusted EPS, management’s narrowed full-year adjusted EPS range of 3.94–4.01 sets an attainable finish to the fiscal year, and consensus for the fourth quarter—revenue of 1.04 billion US dollars and adjusted EPS of 1.13—appears well-calibrated against known mix and margin levers. Among the notes surveyed during the period, the balance of opinions is bullish versus bearish, with the bullish perspective prevailing.

The bull case centers on incremental margin durability and mix. Analysts expect core aftermarket volume and disciplined pricing to help preserve or grind gross margin higher from last quarter’s 34.42% baseline, while the growth of higher-value categories provides added support. The modeled 13.74% year-over-year increase in EBIT to 182.90 million US dollars is seen as achievable if price/mix and operating efficiency remain aligned with recent execution patterns. On earnings, the step-up to 1.13 in adjusted EPS—up 10.82% year over year—is interpreted as consistent with the narrowed full-year framework, with room for upside if revenue lands modestly above the 1.04 billion US dollars consensus.

The bullish read also points to cash discipline as a backstop. The ongoing 0.32 US dollars quarterly dividend is frequently cited as a marker of confidence in cash generation and balance sheet resilience. Previews that adopt a constructive stance note that a steady cash return profile can mitigate valuation sensitivity to single-quarter fluctuations, particularly if management maintains a measured approach to spending while supporting growth in higher-margin lines such as Life Sciences.

On risks, even the positive views acknowledge that order timing between Mobile Solutions and Industrial Products could create quarterly noise, and that gross margin is sensitive to mix within core filtration offerings. However, the general assessment is that any such volatility would likely be oscillatory rather than structural, especially if demand indicators and pricing hold through the quarter. Bulls argue that confirmation of revenue acceleration to 9.64% year-over-year growth, alongside stable or improving margin quality, would validate the current consensus path and support management’s full-year EPS range.

In aggregate, the majority outlook frames the setup as balanced-to-upbeat: a credible path to consensus revenue and earnings, tangible levers to defend margins, and a mix shift opportunity through Life Sciences that could provide incremental upside if execution remains consistent. The result is a predominantly bullish preview stance into August 26, 2026, with attention centered on revenue delivery versus the 1.04 billion US dollars marker, gross margin behavior around the 34.42% baseline, and the read-through for the early part of the next fiscal year.